
Sign up to save your podcasts
Or


Send us Fan Mail
Carlos is the Founder of Lacerta Bio, Lacerta Bio is a pharmaceutical business development consultancy. We work with pharmaceutical, biotechnology, medical device, diagnostic, and other life science companies. We also work with venture capital and private equity firms that invest in these companies.
He is also the CEO of Connexin Therapeutics, Inc. an early-stage glaucoma drug developer. Who has the goal of developing and partner novel connexin inhibitors for retinal neuroprotection secondary to glaucoma and other ophthalmic disease conditions.
In this episode, we discuss his startup Connexin Therapeutics and how things are progressing for a startup that is focused on bringing a Glaucoma drug to market.
By Don Davis PhD, MBA5
1010 ratings
Send us Fan Mail
Carlos is the Founder of Lacerta Bio, Lacerta Bio is a pharmaceutical business development consultancy. We work with pharmaceutical, biotechnology, medical device, diagnostic, and other life science companies. We also work with venture capital and private equity firms that invest in these companies.
He is also the CEO of Connexin Therapeutics, Inc. an early-stage glaucoma drug developer. Who has the goal of developing and partner novel connexin inhibitors for retinal neuroprotection secondary to glaucoma and other ophthalmic disease conditions.
In this episode, we discuss his startup Connexin Therapeutics and how things are progressing for a startup that is focused on bringing a Glaucoma drug to market.

770 Listeners

822 Listeners

6,313 Listeners

29,305 Listeners

20 Listeners

19,731 Listeners

1,324 Listeners